Synthesis and biological investigation of peptidomimetic SARS‐CoV‐2 main protease inhibitors bearing quinoline‐based heterocycles at P 3
Archiv der Pharmazie · 2025
DOI: 10.1002/ardp.202400812 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Sara Rossi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy. Hauptthemen laut MEDLINE: Quinolines, Peptidomimetics, SARS-CoV-2, Coronavirus 3C Proteases. Die Arbeit nennt 39 Literaturangaben. Gefördert von: EU funding within the NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases, Project no. PE00000007, INF-ACT, Project of National Interest PRIN, "Fondo di Beneficenza di Intesa Sanpaolo".
Abstract (Originalsprache)
In the last few years, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been the cause of a worldwide pandemic, highlighting the need for novel antiviral agents. The main protease (M pro ) of SARS‐CoV‐2 was immediately identified as a crucial enzyme for viral replication and has been validated as a drug target. Here, we present the design and synthesis of peptidomimetic M pro covalent inhibitors characterized by quinoline‐based P 3 moieties. Structure–activity relationships (SARs) were also investigated at P 1 and P 2 , as well as for different warheads. The binding modes of the designed inhibitors were assessed using X‐ray crystallographic and molecular docking studies. The identified M pro inhibitors were tested for their antiviral activities in cell‐based assays, and the results were encouraging. The SAR studies presented here can contribute to the future design of improved inhibitors by addressing some of the current or prospective issues regarding M pro inhibitors currently used in therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
- Institute of Molecular Genetics IGM-CNR 'Luigi Luca Cavalli-Sforza', Pavia, Italy.
- Department of Medical Biotechnologies, University of Siena, Siena, Italy.
- Department of Pharmacy, University of Salerno, Fisciano, Salerno, Italy.
- Department of Pharmacy, University of Pisa, Pisa, Italy.
- Department of Molecular Medicine, University of Pavia, Pavia, Italy.
ORCID-Profile: Mariachiara Pieroni, Gabriele Carullo, Giuseppe Campiani
Förderung
- EU funding within the NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases, Project no. PE00000007, INF-ACT
- Project of National Interest PRIN
- "Fondo di Beneficenza di Intesa Sanpaolo"
- AVITHRAPID project, European Union HORIZON-HLTH-2023-DISEASE-03-04
- Italian Association for Cancer Research
Zitieren
APA
Rossi, S., Deidda, G., Fiaschi, L., Ibba, R., Pieroni, M., Dichiara, M., Carullo, G., Butini, S., Ramunno, A., Brogi, S., Lolicato, M., Arrigoni, C., Cabella, N., Bavagnoli, L., Maga, G., Varasi, I., Biba, C., Vicenti, I., Gemma, S., …, & Campiani, G. (2025). Synthesis and biological investigation of peptidomimetic SARS‐CoV‐2 main protease inhibitors bearing quinoline‐based heterocycles at P 3. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400812
Vancouver
Rossi S, Deidda G, Fiaschi L, Ibba R, Pieroni M, Dichiara M, et al. Synthesis and biological investigation of peptidomimetic SARS‐CoV‐2 main protease inhibitors bearing quinoline‐based heterocycles at P 3. Archiv der Pharmazie. 2025. doi:10.1002/ardp.202400812
BibTeX
@article{Rossi2025,
author = {Rossi, Sara and Deidda, Graziano and Fiaschi, Lia and Ibba, Roberta and Pieroni, Mariachiara and Dichiara, Maria and Carullo, Gabriele and Butini, Stefania and Ramunno, Anna and Brogi, Simone and Lolicato, Marco and Arrigoni, Cristina and Cabella, Noemi and Bavagnoli, Laura and Maga, Giovanni and Varasi, Ilenia and Biba, Camilla and Vicenti, Ilaria and Gemma, Sandra and Crespan, Emmanuele and Zazzi, Maurizio and Campiani, Giuseppe},
title = {Synthesis and biological investigation of peptidomimetic SARS‐CoV‐2 main protease inhibitors bearing quinoline‐based heterocycles at P 3},
journal = {Archiv der Pharmazie},
year = {2025},
doi = {10.1002/ardp.202400812}
}
EUVIMED